Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a clinical-stage biotechnology company with a product candidate, Neflamapimod, that has shown potential to improve synaptic dysfunction in age-related neurologic disorders. The company's recent Phase 2a trial in patients with dementia with Lewy bodies (DLB) showed promising results, with the drug slowing disease worsening in patients with low plasma pTau181 levels. With a pivotal trial in DLB planned and potential revenue from other indications, CervoMed has a strong outlook for further success. Additionally, the company's patent position has been strengthened, and mid-stage trial results in patients with non-fluent variant primary progressive aphasia (nfvPPA) are expected shortly. This positive news, along with the potential for a strategic partnership and further clinical successes, indicates a positive outlook for CervoMed's stock.

Bears say

CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The primary product candidate, Neflamapimod, has shown promising results in clinical trials for treating age-related neurologic disorders, particularly in DLB. However, the recent data analysis shows that the dose selection for the pivotal assessment may not be optimal, and there is a risk of future delay in initiating the Phase 3 trial. Additionally, there is a possibility of dilution risk in the medium term, which could impact the company's valuation and stock price.

CervoMed Inc (CRVO) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 4 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.